|Bid||1,485.00 x 175400|
|Ask||1,500.00 x 417900|
|Day's Range||1,485.50 - 1,501.00|
|52 Week Range||1,446.50 - 1,745.56|
|PE Ratio (TTM)||43.70|
|Dividend & Yield||1.01 (5.25%)|
|1y Target Est||N/A|
In the world of patented pharmaceuticals, "first-mover advantage" isn't everything. Glaxo's Zantac ulcer treatment proved as much in the 1980s. Despite being launched years after the pioneering ...
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GlaxoSmithKline Plc Here are 5 ETFs with the largest exposure to GSK-GB. Comparing the performance and risk of GlaxoSmithKline Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)